During the last 15 years, large prospective clinical trials have proven that :
- statin therapy may reduce the risk of major cardiovascular events by 25 to 35%. However, despite effective low-density lipoprotein cholesterol (LDL-C) lowering treatment, significant cardiovascular (CV) risk persists.
- even aggressive multifactorial therapy (statins, blood pressure lowering agents, anti-diabetic agents) did not prevent the development or progression of microvascular complications in patients with type 2 diabetes.
This section propose to put the results of these large clinical trials into perspective both on macro- and microvascular residual risk.
"Accreditation by AACI confirms R3i is to be trusted in the field of Residual Vascular Risk."
The information provided on this website is for educational purposes only and cannot be used for personal medical care. Always seek the advice of a qualified health professional if you have any questions regarding diagnosis and/or management of your specific condition.